Rafferty Asset Management, LLC Uni Qure N.V. Transaction History

Rafferty Asset Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$5.63 - $8.27 $124,203 - $182,444	-22,061 Reduced 5.64%	368,783 $2.5 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $1.29 Million - $2.28 Million	192,785 Added 97.34%	390,844 $2.62 Million
Q2 2023 Aug 11, 2023	SELL	$11.12 - $22.2 $196,701 - $392,695	-17,689 Reduced 8.2%	198,059 $2.27 Million
Q1 2023 May 11, 2023	BUY	$18.7 - $23.07 $338,974 - $418,189	18,127 Added 9.17%	215,748 $4.35 Million
Q4 2022 Feb 13, 2023	SELL	$18.12 - $27.32 $233,240 - $351,663	-12,872 Reduced 6.12%	197,621 $4.48 Million
Q3 2022 Nov 14, 2022	BUY	$16.98 - $25.54 $2.01 Million - $3.02 Million	118,165 Added 127.98%	210,493 $3.95 Million
Q2 2022 Aug 12, 2022	SELL	$13.15 - $20.45 $1.3 Million - $2.01 Million	-98,489 Reduced 51.61%	92,328 $1.72 Million
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $611,915 - $904,827	42,085 Added 28.3%	190,817 $3.45 Million
Q4 2021 Feb 10, 2022	BUY	$20.24 - $36.01 $1.72 Million - $3.06 Million	85,008 Added 133.4%	148,732 $3.09 Million
Q3 2021 Nov 10, 2021	SELL	$26.01 - $38.22 $224,076 - $329,265	-8,615 Reduced 11.91%	63,724 $2.04 Million
Q2 2021 Aug 10, 2021	SELL	$29.97 - $37.17 $3.46 Million - $4.29 Million	-115,473 Reduced 61.48%	72,339 $2.23 Million
Q1 2021 May 10, 2021	BUY	$29.24 - $42.03 $4.69 Million - $6.74 Million	160,257 Added 581.59%	187,812 $6.33 Million
Q4 2020 Feb 10, 2021	BUY	$35.35 - $50.67 $974,069 - $1.4 Million	27,555 New	27,555 $996,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.